Results 51 to 60 of about 25,012 (219)

Psychedelic Architectures: Expanding Universal Care with the Integration of Plural Psychedelic Health Spaces

, 2022
Health, an incredibly personal and multifaceted component of human experience. Our places of health are continuously informed by evolving practices of care.
Mcintosh, Andrea Rose
core   +1 more source

Psychedelic Humanities

Psychedelics are part of a resurgence of interest in consciousness studies, especially as altered states of consciousness are being re-examined in the context of psychedelic-assisted therapies.

core   +5 more sources

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted
Amandine Luquiens, Dahbia Belahda, Carine Graux, Noe Igounenc, Chris Serrand, Paul Rochefort, Thibault Mura, Felix Sergent   +7 more
wiley   +1 more source

On Minimizing Risk and Harm in the Use of Psychedelics

Psychiatric Research and Clinical Practice
Objective This article outlines recommendations from 30 psychedelic researchers on how to create a better psychedelic safety net. Methods A survey of 30 psychedelic researchers asked them to identify key critical research gaps around psychedelic harm and
Jules Evans, Marc Aixalà, Brian T. Anderson, William Brennan, Rebecka Bremler, Joost J. Breeksema, Lisa Burback, Abigail E. Calder, Robin L. Carhart‐Harris, Katherine Cheung, Neşe Devenot, Ingmar Gorman, Jakub Greń, Peter S. Hendricks, Brian Holoyda, Edward Jacobs, Joy Krecké, Daniel J. Kruger, David Luke, Tomislav Majić, Amy L. McGuire, Nicky J. Mehtani, David S. Mathai, Kristin Nash, Tehseen Noorani, Roman Palitsky, Oliver C. Robinson, Otto Simonsson, Elin Stahre, Michiel vanElk, David B. Yaden   +30 more
doaj   +1 more source

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction, EarlyView.
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock, Krista J. Siefried, Gill Bedi, Steven Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett   +8 more
wiley   +1 more source

Perceived attachment history predicts psychedelic experiences : A naturalistic study

Background and aims: Emerging research indicates that psychedelics may have therapeutic potential by fostering meaningful experiences that act as in fl ection points in people ' s narratives of personal development.
Mikulincer, Mario, Granqvist, Pehr,, Gruneau Brulin, Joel,, Mario Mikulincer, Joel Gruneau Brulin, Cherniak, Aaron,, Aaron D. Cherniak, Pehr Granqvist   +7 more
core   +1 more source

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source

Synergistic behavioral and neuroplastic effects of psilocybin-NMDAR modulator administration

Translational Psychiatry
The full therapeutic potential of serotonergic psychedelics (SP) in treating neuropsychiatric disorders, such as depression and schizophrenia, is limited by possible adverse effects, including perceptual disturbances and psychosis, which require ...
Tom Ben-Tal, Ilana Pogodin, Alexander Botvinnik, Tzuri Lifschytz, Uriel Heresco-Levy, Bernard Lerer   +5 more
doaj   +1 more source

The psychoactive effects of repeated ketamine infusions and their mechanistic role in the treatment of alcohol use disorder: Secondary analysis of a randomised controlled trial

Addiction, EarlyView.
Abstract Background and aims Ketamine assisted psychotherapy is a promising new treatment for alcohol use disorder (AUD). The psychoactive effects of repeated intravenous (IV) ketamine infusions in people with AUD and their mechanistic role in treating AUD are largely unknown.
Cassie Bloy, Ananya Sarma, Bethan Marsh, Lorna Hardy, Meryem Grabski, Merve Mollaahmetoglu, Joshua Shotton, Shamhethan Bhaskaran, Anne Lingford‐Hughes, H. Val Curran, Celia Morgan, Will Lawn   +11 more
wiley   +1 more source

Psychedelic-like Activity of Norpsilocin Analogues

Primary metabolites of mushroom tryptamines, psilocybin and baeocystin (i.e., psilocin and norpsilocin), exhibit potent agonist activity at the serotonin 2A receptor (5-HT2A) in vitro but differ in their 5-HT2A-mediated effects in vivo.
Elise K. Burkhartzmeyer (16033367), Michael H. Baumann (8785529), Alexander M. Sherwood (3395678), Grant C. Glatfelter (10277528), Samuel E. Williamson (4436167)   +4 more
core   +1 more source